Cytodyn Inc (CYDY)

[BlackDoggie]

“The exception that proves the rule” is an asinine saying lacking real meaning. What ARNA shows, and what you seem to refuse to acknowledge, is that not all R/S are created equally. Most are executed by failing companies, so they fail. Some are value creating propositions because the increased visibility and liquidity can benefit companies with something to bring to the table. Amateur17 has it right - if there’s no good news to go with the R/S, the price will absolutely lag. Your blind refusal to acknowledge that there may be factors impacting the future value of the company beyond an accounting maneuver shows that you’re either ill informed or not well meaning. I assume the latter, since you just showed up.

Even most small, pre-revenue biotech’s who R/S to uplist differ from CYDY. Most I’ve found are early to mid-stage clinical - nowhere near as far along as CYDY. I expect this to make a significant difference. You need news to go with the R/S, and hey have several meaningful possibilities to supply that news with late-stage clinical trials for a disruptive drug in a large market.

By the way, C’s stock price after the R/S was ~$45. It now trades around $75. Most analysts cite that as a success. There are other examples (AIG, Priceline..) but I doubt you care.